SEC Form SC 13G/A filed

2/16/21 12:23:48 PM ET

Biotechnology: Laboratory Analytical Instruments

Industrials

Get the next $A alert in real time by email

SC 13G/A 1 a13gadec20.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10) AGILENT TECHNOLOGIES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 00846U101 (CUSIP NUMBER) December 31, 2020 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. ROWE PRICE ASSOCIATES, INC. 52-0556948 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 8,602,041 6. Shared Voting Power* 0 7. Sole Dispositive Power* 23,512,823 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 23,512,823 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 7.6% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: AGILENT TECHNOLOGIES, INC. Item 1(b) Address of Issuer's Principal Executive Offices: 5301 STEVENS CREEK BLVD, SANTA CLARA, CALIFORNIA 95051 Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. ("Price Associates") Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 00846U101 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class Not Applicable Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. (2) With respect to securities owned by any one of the T. Rowe Price Funds, only the custodian for each of such Funds, has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. No other person is known to have such right, except that the shareholders of each such Fund participate proportionately in any dividends and distributions so paid. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: February 16, 2021 Signature: /s/ David Oestreicher Name & Title: David Oestreicher, Executive Vice President 12/31/2020

Get the next $A alert in real time by email

Recent Analyst Ratings for

Date	Price Target	Rating	Analyst
8/28/2024	$157.00	Overweight	Wells Fargo
7/10/2024	$135.00 → $150.00	Neutral → Buy	Citigroup
6/27/2024		Outperform → Peer Perform	Wolfe Research
6/3/2024	$135.00	Hold	Jefferies
4/5/2024	$145.00 → $163.00	Hold → Buy	Stifel
12/13/2023	$140.00	Outperform	Wolfe Research
12/12/2023	$130.00 → $133.00	Buy → Neutral	BofA Securities
11/17/2023	$163.00 → $125.00	Buy → Neutral	UBS

More analyst ratings

SEC Form SC 13G/A filed

Chat with this insight

Recent Analyst Ratings for $A

$A Market Insights

Live Market Insights

(A) - Analyzing Agilent Technologies's Short Interest

Agilent Technologies To Acquire BIOVECTRA For $925M, Expanding End-To-End Biopharma Solutions For Accelerated Drug Discovery And Development

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,200 Today

$A SEC Filings

Agilent Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

SEC Form 424B5 filed by Agilent Technologies Inc.

SEC Form 8-K filed by Agilent Technologies Inc.

$A Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Wells Fargo initiated coverage on Agilent with a new price target

Agilent upgraded by Citigroup with a new price target

Agilent downgraded by Wolfe Research

$A Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Senior Vice President Riemann Angelica was granted 1,045 shares and covered exercise/tax liability with 327 shares, increasing direct ownership by 5% to 15,896 units (SEC Form 4)

Sr. VP and CFO Mcmahon Robert W. was granted 7,835 shares and covered exercise/tax liability with 2,196 shares, increasing direct ownership by 4% to 166,115 units (SEC Form 4)

President and CEO Mcdonnell Padraig was granted 4,505 shares and covered exercise/tax liability with 1,506 shares, increasing direct ownership by 13% to 26,355 units (SEC Form 4)

$A Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Agilent Technologies Inc.

SEC Form SC 13G filed by Agilent Technologies Inc.

SEC Form SC 13G filed by Agilent Technologies Inc.

$A Financials

Live finance-specific insights

Agilent Increases Cash Dividend to 24.8 Cents per Share

Agilent to Announce Fourth-Quarter Fiscal Year 2024 Financial Results on Nov. 25

Agilent Announces Cash Dividend of 23.6 Cents per Share

$A Leadership Updates

Live Leadership Updates

Agilent to Acquire North American CDMO BIOVECTRA

Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

Agilent Unveils the 8850 Gas Chromatograph: A Leap Forward in Analytical Excellence

$A Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Gonsalves Rodney (Amendment)

Gonsalves Rodney bought $288 worth of shares (3 units at $111.09), increasing direct ownership by 0.01% to 24,222 units (SEC Form 4)

$A Press Releases

Fastest customizable press release news feed in the world

Agilent Increases Cash Dividend to 24.8 Cents per Share

Agilent 2024 Early Career Professor Award Presented to Adeyemi Adeleye

Agilent Announces the Innovative Mito-rOCR Assay Kit for Mitochondrial Research

Recent Analyst Ratings for
$A

$A
Market Insights

$A
SEC Filings

$A
Analyst Ratings

$A
Insider Trading

$A
Large Ownership Changes

$A
Financials

$A
Leadership Updates

$A
Insider Purchases

$A
Press Releases